Canada’s Biomanufacturing Expansion Needs More Than Scientists

Canada’s life sciences sector is entering a pivotal growth phase. New investments in biomanufacturing, biologics, cell and gene therapies, and advanced therapeutics are accelerating across the country, from Toronto and Hamilton to Montreal and Vancouver.

But while new facilities, equipment, and funding are expanding quickly, one critical constraint remains: talent.

The challenge is no longer limited to finding research scientists or PhD-level innovators. Today, many of the hardest-to-fill roles in life sciences hiring sit outside the lab, in the operational functions required to move innovation from discovery to commercial production.

Canada’s Biomanufacturing Growth Is Accelerating

In the years following the pandemic, Canada made rebuilding domestic biomanufacturing capacity a national priority. Federal and provincial governments have invested heavily to strengthen vaccine, biologics, and therapeutic production capabilities.

Canada’s Biomanufacturing and Life Sciences Strategy has already directed more than $2.5 billion into 43 projects nationwide, supporting domestic manufacturing, vaccine production, and therapeutic innovation.

Major recent investments continue to reinforce this momentum:

• OmniaBio’s Hamilton expansion, supported by federal investment, is helping scale AI- and robotics-enabled cell and gene therapy manufacturing, reinforcing Canada’s growing focus on advanced therapeutic production and specialized biomanufacturing talent.
• In 2026, the federal government announced $127 million in new funding for life sciences projects including Aspect Biosystems in British Columbia.
• Provinces such as Ontario and Quebec continue expanding support for biologics, advanced therapeutics, and precision medicine ecosystems.

This investment reflects a strategic shift. Canada is no longer focused solely on research excellence. The goal is end-to-end capability: discovery, scale-up, manufacturing, commercialization, and supply resilience. This transition changes the talent equation dramatically.

Biomanufacturing Is Part of Canada’s Major Projects Growth Strategy

Biomanufacturing is increasingly becoming part of Canada’s major projects economy. Much like investments in EV battery manufacturing, clean energy, aerospace, and critical minerals, life sciences infrastructure is now viewed as strategically important to Canada’s long-term economic resilience and supply chain security.

Recent investments such as Moderna’s advanced manufacturing facility in Laval highlight Quebec’s growing importance in Canada’s life sciences ecosystem. Beyond research, these projects are creating high-value Quebec jobs in production, validation, engineering, automation, maintenance, and quality systems—roles that are essential to scaling biomanufacturing safely and efficiently. Moderna’s Laval site also signals how Quebec is becoming increasingly important to Canada’s major projects strategy in healthcare and advanced manufacturing.

For employers, this means biomanufacturing is no longer just a research story. It is increasingly a workforce planning story tied to industrial growth, regional competitiveness, and Canada’s major projects agenda.

The Talent Gap Is Moving Beyond R&D

When many people think of life sciences recruitment, they think of research scientists, microbiologists, or clinical researchers. These roles remain critical, but they are no longer the only pressure point.

As biomanufacturing facilities move from pilot production to commercial scale, demand is rising for professionals who understand highly regulated manufacturing environments and can maintain operational reliability. This includes roles such as:

• GMP Production Supervisors
• Quality Assurance Specialists
• Validation Engineers
• Process Engineers
• Maintenance Technicians
• Automation and Controls Specialists
• Regulatory Affairs Professionals
• Technical Operations Leaders

These roles sit at the intersection of science, engineering, compliance, and production. That combination is rare and requires strategic workforce planning and talent pipeline curation.

BioTalent Canada estimates Canada’s bio-economy will need 65,000 additional workers by 2029 to support growth. More concerning, labour supply for biomanufacturing and production roles may meet less than 25% of projected demand.

For employers, that means hiring competition is likely to intensify, not ease. “Canada’s investment in biomanufacturing is creating tremendous opportunity, but facilities alone do not create capacity. Success depends on having the skilled people needed to operate, validate, and scale these environments safely and efficiently. Employers that plan for workforce needs early will be best positioned to grow.” Scott Murphy, President, Operational Staffing & Life Sciences, Agilus by Synergie

Why GMP Experience Has Become a Critical Hiring Requirement

One of the biggest barriers to scaling biomanufacturing talent is regulatory complexity.

Unlike traditional manufacturing environments, life sciences production requires strict adherence to Good Manufacturing Practices (GMP). Every process, equipment calibration, validation protocol, and batch record must meet rigorous quality and regulatory standards. That makes hiring especially difficult.

Employers are not simply looking for candidates with manufacturing experience. They need talent with:

• Cleanroom experience
• GMP documentation expertise
• Validation and qualification knowledge
• CAPA and deviation management experience
• Regulatory inspection readiness

These capabilities are developed through hands-on experience in highly controlled environments.

They cannot be built overnight. Even strong engineering or operations professionals from adjacent sectors often need substantial onboarding before becoming fully productive in biomanufacturing settings.

Infrastructure Can Be Built Faster Than Talent Pipelines

Educational institutions are expanding programs in biotechnology, pharmaceutical sciences, and biomedical engineering. Industry associations are also investing in upskilling initiatives.

But workforce development naturally moves slower than capital investment. As new facilities open, employers often find themselves competing for the same limited pool of experienced GMP professionals. In many cases, organizations are hiring from competitors rather than expanding the total talent pool. That approach may solve short-term staffing needs but does little to improve long-term workforce capacity or retention.

What Life Sciences Employers Should Do Now

Employers that wait until commissioning or scale-up to think about hiring often find themselves behind. The strongest organizations are taking a more proactive approach by:

Building talent pipelines earlier – Critical hiring should begin well before production ramps up.

Expanding adjacent talent pools – Manufacturing, food processing, medtech, aerospace, and highly regulated industrial sectors may offer transferable skills.

Investing in training and upskilling – Not every role requires a fully experienced candidate on day one.

Partnering with specialized recruiters – Access to passive talent and niche technical networks can significantly shorten time-to-fill.

As facilities become more sophisticated, hiring strategies must evolve alongside them.

The Future of Biomanufacturing in Canada Depends on Workforce Readiness

Canada has made significant progress rebuilding domestic biomanufacturing capacity.

The infrastructure is coming. The capital is flowing. The science is strong. The next challenge is operational readiness.

Biomanufacturing expansion is ultimately a workforce challenge as much as a scientific one.

For life sciences employers, the demand for specialized talent is already high, so the immediate question is whether your hiring strategies are evolving quickly enough to keep pace.

About Agilus by Synergie

Agilus by Synergie helps life sciences employers across Canada hire specialized talent in regulated and high-growth environments. From GMP manufacturing and quality assurance to validation, engineering, technical operations, and leadership roles, our recruiters understand the unique hiring challenges facing today’s life sciences sector.

Whether you are scaling a new facility, supporting one of Canada’s major projects, or expanding operations and hiring for critical Quebec jobs, Agilus can help you build the workforce needed to deliver safely, efficiently, and at scale.

FAQs About Biomanufacturing Hiring in Canada

What is biomanufacturing?

Biomanufacturing is the production of biologics, vaccines, cell and gene therapies, and other therapeutic products using living systems such as cells or microorganisms.

Why is biomanufacturing growing in Canada?

Government investment, pandemic preparedness, domestic supply resilience, and growing demand for advanced therapeutics are driving expansion across Canada.

Why does biomanufacturing matter to Canada’s major projects?

Biomanufacturing is increasingly considered part of Canada’s major projects strategy because domestic production supports economic resilience, supply chain security, and long-term industrial growth.

Why are Quebec jobs important to biomanufacturing growth?

Quebec is one of Canada’s strongest life sciences hubs, with growing demand for specialized talent across GMP manufacturing, validation, quality assurance, and technical operations.

Which life sciences roles are hardest to hire?

Many employers struggle to hire GMP manufacturing professionals, QA specialists, validation engineers, regulatory professionals, and technical operations leaders.

Why is GMP experience so valuable?

GMP experience helps ensure products are manufactured safely, consistently, and in compliance with strict regulatory requirements.

How can life sciences employers improve hiring?

Organizations can improve hiring by planning earlier, widening talent pools, investing in training, and partnering with specialized recruitment experts.